Warton: 3mL of plasma at 1h 4C, or 4D at RT. EDTA - lots of lysis, may be apoptotic ladder. HMW DNA w/Streck #MDxEU17
9:44am April 11th 2017 via Hootsuite
Warton: After 1h at 4C, looked at difference between 30' and 60' protease digest time - 60' raised the yield. Noisy data. #MDxEU17
9:42am April 11th 2017 via Hootsuite
Warton: The challenges of collecting samples - Streck BCT, QIAGEN ccfDNA. Sees more competition (i.e. MagBio) in this area #MDxEU17
9:40am April 11th 2017 via Hootsuite
Warton: Presents a few examples of using different gene markers for monitoring - GSTP1, 6-gene panel in mBC, #MDxEU17
9:39am April 11th 2017 via Hootsuite
Warton: '16 PNAS tissue-spec methylation https://t.co/af40BTOQz1 Goes back to genes by tissue and prognostic value, incl negatives #MDxEU17
9:36am April 11th 2017 via Hootsuite
Warton: A SEPT9 methylation test is already approved in stool. One problem is gene-spec DNA may be specific to a different tissue #MDxEU17
9:33am April 11th 2017 via Hootsuite
Warton: Shows data from this '13 Vogelstein rev https://t.co/bC9m29kAoN and examples from this '08 ref https://t.co/xS4wXiVmIO #MDxEU17
9:31am April 11th 2017 via Hootsuite
Warton: DNA methylation tends to change 'in whole regions' in cancer tissues. GSTP1 >90% in prostate; HOXA9 >95% in ovarian etc #MDxEU
9:28am April 11th 2017 via Hootsuite
Warton: Methylation can be assayed 'by the cheap and cheerful' method of PCR. Can bisulfite treat, 5MeC unchanged, C changes to U #MDxEU17
9:27am April 11th 2017 via Hootsuite
Warton: Dx information is useful before you know anything about it. Methylation at CpG sites reviewed - CpG islands at transc start #MDxEU17
9:25am April 11th 2017 via Hootsuite
Warton: Post ca diagnosis, low or high ctDNA can be prognostic. Post surgery, post chemo, monitoring can help #MDxEU17
9:24am April 11th 2017 via Hootsuite
Warton: Shows figure from '16 ref https://t.co/RC03QB8Yb6 For monitoring cp to Dx, the bar is much lower. FP's not as big a prob #MDxEU17
9:22am April 11th 2017 via Hootsuite
Kristina Warton (Garvan Inst Sydney AU) Methylated circulating DNA in monitoring cancer treatment response #MDxEU17
9:20am April 11th 2017 via Hootsuite
Patel: ctDNA levels may not be freq enough to detect more frequent perturbation (during Tx). A new way to think of resp. monitoring #MDxEU17
Patel: The kinetics bear this out: imaging slow decline along with protein marker decline; but ctDNA quickly diminishes. #MDxEU17
9:18am April 11th 2017 via Hootsuite
Patel: Protein markers are secreted from live cancer cells, while ctDNA is released from dying cancer cells w/active clearing #MDxEU17
9:17am April 11th 2017 via Hootsuite
Hmm. https://t.co/E3JHIEbcp9
9:13am April 11th 2017 via Hootsuite
Q: Expense for daily Dx use? O'Brien: 100€ per sample. #MDxEU17
7:28am April 11th 2017 via Hootsuite
O'Brien: qPCR gene expression from the CTCs isolated, looking at early stg Ov Ca, n=200 from Parsortix harvest #MDxEU17
7:26am April 11th 2017 via Hootsuite
O'Brien: Points to this Dec '15 ref https://t.co/S07vQ8Eue6 from CRUK (Dive group) Fig from '15 PLoS https://t.co/htPpGSCzbI #MDxEU17
7:24am April 11th 2017 via Hootsuite
O'Brien: 10mL of whole blood, can label cells in-cassette. 2K-5K WBC background (to pool collected CTCs) or feed DEPArray #MDxEU17
7:20am April 11th 2017 via Hootsuite
O'Brien: A stepped channel, the larger CTCs will get caught. Can be stained or reverse flushed. Shows video of device in action #MDxEU17
7:17am April 11th 2017 via Hootsuite
O'Brien: Parsortix - selection via size and deformability. Wanted a system to get cells recovered, from pt samples. #MDxEU17
7:14am April 11th 2017 via Hootsuite
O'Brien: CTC and ctDNA failed in 20-30%; when both 100% detected T790M in these samples #MDxEU17
7:12am April 11th 2017 via Hootsuite
O'Brien: Believe that CTC and ctDNAs are complementary. Shows a nice chart - Solid vs liquid biopsy https://t.co/UtxlQViUuO #MDxEU17
Michael O'Brien (ANGLE plc): Parsortix: utilise both cfDNA and CTCs from a single patient sample #MDxEU17
7:07am April 11th 2017 via Hootsuite
Winter: "No longer a game of chess, more like an infinite game of Minecraft" as far as tackling cancer. #MDxEU17
7:04am April 11th 2017 via Hootsuite
Winter: IDH1 - found in CNS (GBM), AML. For ICC, seen in about 13%. Will do WES for new mutations, looking for circ metabolites #MDxEU17
7:00am April 11th 2017 via Hootsuite
Winter: #MDxEU17 Interhepatic cholangiocarcinoma (ICC) is a cancer w/unmet need '16 ref https://t.co/IMmyudgS5l 4pt analysis, found CNA Ch12
6:59am April 11th 2017 via Hootsuite
Winter: With n=16, 9/16 response on CT correlated w/ctDNA. 3/16 equivocal, rest did not. #MDxEU17
6:56am April 11th 2017 via Hootsuite
Winter: Adv chemorefractory in lung SIRT (selective internal radiation). High level of ctDNA had short OS. May help in pt select #MDxEU17
6:55am April 11th 2017 via Hootsuite
Winter: KRAS concord 92%; up to 1500 days, one had KRAS wt but ctDNA mutant. (But tissue not sampled again.) #MDxEU17
6:52am April 11th 2017 via Hootsuite
Winter: Showed tumor vs plasma mutation status. Time from FFPE KRAS, and detection in ctDNA in refractory population. <1y to 3y #MDxEU17
6:51am April 11th 2017 via Hootsuite
Winter: #MDxEU17 Rcent review https://t.co/JAE19BAuNH PERFORM clin trial for CT / MRI, Looking at KRAS status with mCRC
6:50am April 11th 2017 via Hootsuite
Winter: Intra-arterial brachytherapy - use bloodflow to hepatic mets, to use perfusion imaging #MDxEU17
6:47am April 11th 2017 via Hootsuite
Winter: First is vessel embolisation, treated with Yttrium-90 spheres, followed by Y90 PET to see where internal radiation is #MDxEU17
Winter: She takes care of many pts at the end of disease. Liver MDT - Figure from '14 ref https://t.co/rEs8gFvNLK 2-part procedure #MDxEU17
6:46am April 11th 2017 via Hootsuite
Helen Winter (Univ Oxford) Monitoring and sequencing cell-free DNA in pts receiving selective internal radiation #MDxEU17
6:45am April 11th 2017 via Hootsuite
Q: Outcome and OS for pts w/T790M? Plagnol: Need more pts to answer this question completely, trend promising #MDxEU17
6:44am April 11th 2017 via Hootsuite
Plagnol: A2 About 3-5% over 50yo have intriguing KRAS or other mutations. #MDxEU17
6:43am April 11th 2017 via Hootsuite
Q: Healthy volunteers? Plagnol: A key question; answer is 'it depends on the cohort'. 50yo vs. young people, smokers etc. #MDxEU17
6:42am April 11th 2017 via Hootsuite
Q: Sure that TP53 is in the tumor in example? Plagnol: Seen in other pts, where TP53 doesn't change. Intriguing. #MDxEU17
Plagnol: Building the case with clinical data to support widespread use. #MDxEU17
6:41am April 11th 2017 via Hootsuite
Plagnol: Accumulating evidence support its use as a replacement for tissue biopsy. Commercial avail in US this year (2017) #MDxEU17
6:40am April 11th 2017 via Hootsuite
Plagnol: Many questions remain - what about TP53 mutants that stay steady thru treatment? #MDxEU17
Plagnol: T790M det in 50% of NSCLC pts, detected down to 0.1% MAF. Freq of T790M showed no correlation to response #MDxEU17
6:38am April 11th 2017 via Hootsuite
Plagnol: 'Rather than rush a product to market", want to design clinical studies. '17 ref https://t.co/gJBJ0r2zPo T790M det #MDxEU17
6:37am April 11th 2017 via Hootsuite
Plagnol: Correlation of mutational profile pre-trtmt and ctDNA allele fx response post-treatment #MDxEU17
6:36am April 11th 2017 via Hootsuite
Plagnol: Showed sensitivity data down to 0.5%. Showed pt data showed complete metabolic response w/T790M resist mut #MDxEU17
6:34am April 11th 2017 via Hootsuite
Plagnol: Their InVision panel covers Fusions, SNVs, indels, amplifications. Some with full gene coverage, ALK/RET fusions. #MDxEU17
6:31am April 11th 2017 via Hootsuite
